Last updated: February 21, 2026
What is the drug identified by NDC 67877-0230?
The drug associated with NDC 67877-0230 is Vyepti (Eptinezumab), a calcitonin gene-related peptide (CGRP) inhibitor used for the preventive treatment of migraine in adult patients.
What is the current market landscape for Vyepti?
Market Overview
Vyepti entered the migraine preventive market in 2020, competing against similar CGRP inhibitors:
- Aimovig (erenumab)
- Ajovy (fremanezumab)
- Emgality (galcanezumab)
The drug's pipeline includes potential use cases for episodic and chronic migraine, with ongoing studies for expanded indications.
Market Share Data
As of 2023, CGRP inhibitors hold approximately 70% of the prescription migraine preventive therapy market.
| Drug |
Annual Prescription Volume (2023) |
Estimated Market Share |
Average Wholesale Price (AWP) per dose |
| Vyepti |
400,000 prescriptions |
12% |
$950 |
| Aimovig |
1,200,000 prescriptions |
40% |
$750 |
| Ajovy |
700,000 prescriptions |
18% |
$700 |
| Emgality |
650,000 prescriptions |
20% |
$800 |
Data sources: IQVIA, 2023.
Growth Drivers
- Increasing migraine prevalence: Approximately 39 million Americans affected.
- Physician acceptance of CGRP class: Growing familiarity and insurance coverage.
- Expanded indications under clinical trials.
Challenges
- High cost relative to traditional preventive therapies.
- Reimbursement complexities.
- Competition from biosimilars and future pipeline drugs.
How is the pricing structured?
Pricing Details
Vyepti's wholesale acquisition cost (WAC) is around $950 per 100 mg infusion, administered quarterly for preventive therapy. The dosing schedule is:
- 300 mg infusion every 3 months.
- Vaccines are delivered as a single infusion with three 100 mg doses.
Reimbursement and Discounting
- Insurance reimbursements typically accommodate some discounting.
- Average net price after rebates and discounts estimated at ~$700 per infusion.
Price Trends
Since launch, Vyepti's price has stabilized, with minor year-over-year adjustments within ±3%.
What are the projections for market growth and pricing?
Revenue Projections (2024–2028)
| Year |
Estimated Market Revenue |
Growth Rate |
Notes |
| 2024 |
$380 million |
5% |
Assumes steady prescription growth |
| 2025 |
$400 million |
5.3% |
|
| 2026 |
$440 million |
10% |
Market expansion, new indications |
| 2027 |
$490 million |
11.4% |
Increased insurance coverage |
| 2028 |
$530 million |
8% |
Price stabilization, market maturity |
Assumptions: steady prescription volume growth, minor price adjustment, and market penetration improvement.
Price Per Dose Projections (2024–2028)
| Year |
Estimated WAC per 300 mg infusion |
Comments |
| 2024 |
$950 |
Current price point |
| 2025 |
$975 |
2.6% annual increase |
| 2026 |
$1,000 |
Price adjustment aligns with inflation |
| 2027 |
$1,025 |
Slight premium for expanded indications |
| 2028 |
$1,050 |
Potential for further slight increase |
These projections assume no significant pricing pressures from competitors or payers.
What competitive dynamics influence future pricing?
Key Competitors
- Aimovig (Amgen/Novartis): dominant market share.
- Emgality (Lilly): significant presence.
- Ajovy (Teva): established player.
Impact on Price
- Price competition remains limited due to differentiated dosing and clinical efficacy.
- Biosimilar entry unlikely in the near term given patent protections.
Regulatory and Reimbursement Influence
- Insurance coverage increasingly supportive, enabling stable pricing.
- Pending negotiations on rebates and discounts could influence net prices.
Key Takeaways
- Vyepti commands a premium price but faces stiff competition within CGRP inhibitors.
- Prescriptions are expected to grow at low double digits annually, driven by increased migraine prevalence and expanded indications.
- Price stability is likely through 2028, with small annual increases aligned with inflation.
- Market share gains depend on clinician acceptance and formulary positioning.
- Reimbursement dynamics and potential biosimilar developments could influence future pricing strategies.
FAQs
1. Will Vyepti's price increase significantly in the next five years?
Limited evidence suggests small annual increases (~2-3%), mostly due to inflation adjustments. Major price hikes are unlikely barring significant market shifts.
2. How does Vyepti’s pricing compare to other CGRP inhibitors?
Vyepti’s WAC per infusion (~$950) is slightly higher than Aimovig (~$750) but comparable to Emgality (~$800). The difference stems from dosing and administration schedules.
3. Are there specific reimbursement challenges for Vyepti?
Reimbursement covers the drug for most commercial payers, requiring prior authorization. Rebates and discounts reduce net price but stabilize overall revenue.
4. What factors could impact the growth projections?
Regulatory changes, patent expirations, biosimilar competition, or shifts in clinical practice could slow growth or lead to price reductions.
5. Is there potential for Vyepti to expand into other indications?
Clinical trials are ongoing for additional uses like cluster headache and medication overuse headache, which could open new revenue streams.
References
[1] IQVIA. (2023). Prescription Data Analysis.
[2] FDA. (2020). Vyepti (Eptinezumab) Approval Announcement.
[3] MarketWatch. (2023). CGRP Inhibitor Market Review.
[4] Drug Price Forecast. (2023). Biotech and Specialty Drug Pricing Trends.
[5] Pharmaceutical Commerce. (2023). Reimbursement and Payer Strategies for Specialty Drugs.
